Long non‐coding RNA Fer‐1‐like protein 4 suppresses oncogenesis and exhibits prognostic value by associating with miR‐106a‐5p in colon cancer

Novel long non‐coding RNA Fer‐1‐like protein 4 (FER1L4) has been confirmed to play crucial regulatory roles in tumor progression. It exerts an impact on tumor suppression and functions as a competing endogenous RNA (ceRNA) by sponging miR‐106a‐5p in gastric cancer. However, its clinical significance in colon cancer is completely unknown. The aim of the present study was to annotate the role of FER1L4 and its clinical value in colon cancer. The results showed the aberrant expression of FER1L4 and miR‐106a‐5p in colon cancer tissues. In addition, significant negative correlation between FER1L4 and miR‐106a‐5p expression levels was observed. Among the colon cancer cell lines, FER1L4 levels were relatively lower, with concurrent high levels of miR‐106a‐5p. Restoration of FER1L4 decreased the expression of miR‐106a‐5p, and had a significant influence on colon cancer cell proliferation, migration and invasion. The FER1L4 expression was correlated with depth of tumor invasion, lymph node metastasis, vascular invasion and clinical stage. Moreover, striking differences in overall survival and disease‐free survival were observed for the cases with both low FER1L4 expression and high miR‐106a‐5p expression compared with cases with high FER1L4 expression and low miR‐106a‐5p expression. Circulating FER1L4 and miR‐106a‐5p levels were decreased and increased, respectively, in colon cancer patients after surgery. Our findings indicated that FER1L4 could exert a tumor suppressive impact on colon cancer, which at least, in part, through suppressing miR‐106a‐5p expression, and depletion of FER1L4, alone or combined with overexpression of miR‐106a‐5p, is predictive of poor prognosis in colon cancer and may play a crucial role in cancer prevention and treatment.     

Transjugular intrahepatic portosystemic shunt plus embolization for bleeding esophagojejunal varices after total gastrectomy

A 64-year-old man was admitted to our hospital with hematemesis and melena. Six years ago, he had undergone total gastrectomy with Roux-en-Y esophagojejunostomy for gastric cancer. Endoscopic examination revealed varicose veins at the anastomotic sites with cherry-red spots and hemorrhage. Abdominal computed tomography showed that the varices were supplied by a dilated jejunal vein. Transjugular intrahepatic portosystemic shunt (TIPS) and variceal embolization were performed. There were no major complications or episodes of bleeding during the three-month follow-up. We conclude that TIPS in combination with varices obliteration is an effective alternative method for treatment of ruptured esophagojejunal varices after total gastrectomy.     

复合益生菌制剂对急性坏死性胰腺炎大鼠的保护作用

背景:肠道细菌易位是重症急性胰腺炎(SAP)时胰腺坏死感染的主要来源,因此保护肠黏膜屏障对SAP的治疗具有重要意义。目的:探讨复合益生菌制剂对急性坏死性胰腺炎(ANP)大鼠肠黏膜屏障和胰腺损伤的保护作用。方法:50只SPF级大鼠随机分为假手术组(n=10)、ANP模型组(n=20)和益生菌干预组(n=20)。采用胰腺被膜下均匀注射牛磺胆酸钠制备ANP模型,干预组术前30 min以双歧杆菌四联活菌片溶液灌胃。术后6 h采集标本,检测血淀粉酶、二胺氧化酶(DAO)、TNF-α水平,观察胰腺组织病理学表现和末端回肠组织超微结构。结果:ANP模型组血淀粉酶、DAO、TNF-α水平和胰腺组织学评分均显著高于假手术组(P<0.05),益生菌干预组各项指标均较ANP模型组有所改善(P<0.05)。假手术组末端回肠黏膜结构完整;ANP模型组回肠黏膜上皮细胞微绒毛萎缩、排列稀疏,细胞间连接松弛;益生菌干预组微绒毛稍稀疏,细胞间连接紧密度较ANP模型组增高。结论:复合益生菌制剂对ANP大鼠具有保护作用,不仅能减轻肠黏膜损伤,保护肠黏膜屏障功能,还能减轻胰腺局部损伤和全身性炎症反应。     

红霉素肠溶颗粒和肠溶片的相对生物利用度

红霉素碱肠溶片不便于小儿分剂量服用,我们研制了一种肠溶颗粒新剂型。本文采用微生物法(琼脂打孔法)测定了12名健康志愿者单剂量交叉口服三种不同工艺和辅料制成的红霉素肠溶颗粒(EI、EII、EIII)及一种市售红霉素肠溶片(EIV)各500mg后的血药浓度,经计算机处理:EI、EII和EIII之间各药代动力学参数都较接近(P>0.5),体内吸收(t_(lag)、t_(max)和K_a)均比EIV快(P<0.05),且个体差异小,血峰浓度(C_(max))分别是EIV的1.15、1.30和1.34倍,相对生物利用度(颗粒AUC/片剂AUC)分别为126.3、136.1和133.3％。     

白头翁糖蛋白的分离纯化及其性质

从中药白头翁根的水提取液中分离纯化得均一的糖蛋白组分PcG－A。它由木糖和葡萄糖组成，摩尔比为1．5：1，分子量6．25×104，糖含量61．8％，并含有10种氨基酸。初步分析表明PcG－A为非O-连接的糖蛋白。     

碳酸锂联合131碘治疗Graves病疗效与甲减风险的前瞻性研究

目的探讨碳酸锂联合小剂量131碘在Graves病治疗后5年总有效率和甲状腺功能减退的发生率。方法对比常规同位素及碳酸锂联合131碘治疗Graves病患者后分别于3个月、6个月、1年、1.5年、2年、3年、4年、5年时随访甲状腺功能,观察治疗效果(治愈率和甲状腺功能减退发生率)。结果①入组女性68例,男性36例,年龄在26~58岁之间。常规治疗组与碳酸锂组之间在性别构成、年龄、初治率、甲状腺大小、甲状腺功能方面差异无统计学意义。②常规治疗组和碳酸锂组两组之间碘的剂量分别为4.8mci及3.3mci(P<0.05)。同时所需碘剂的花费分别为(1980±249)元及(1538±202)元,两组之间费用比较,差异有统计学意义(P<0.05)。③常规治疗组和碳酸锂组两组治疗前后显示:常规组及碳酸锂组均能有效的治疗Graves病,前后对比差异有统计学意义。两组之间比较发现:常规组的治愈率明显低于碳酸锂组(P<0.05),而甲减的发生率又高于碳酸锂组(P<0.05)。结论碳酸锂联合131碘治疗Graves病可以增加治愈率,减少甲减的发生率,同时明显减少131碘的剂量,降低费用。     

社区老年人脂肪肝检出情况分析

目的：了解社区老年人脂肪肝的发病情况,以便提出针对性的防治措施。方法对2951名65岁以上社区老年人健康体检的肝脏B超检查结果进行分析。结果检出脂肪肝692名,检出率为23.45%,脂肪肝检出率女性高于男性,且与年龄有一定相关性。结论社区老年人脂肪肝发生率高,要强化自我保健意识,改变不良生活方式,早期防治脂肪肝。     

参附注射液对猪创伤性心脏骤停复苏后肾损伤的保护作用研究

目的探讨参附注射液对猪创伤性心脏骤停复苏后肾损伤的保护作用。方法国产健康雄性白猪21头,采用随机数字表法分为假手术组(Sham组,n=5)、创伤性心脏骤停复苏(TCA组,n=9)和参附组(SFI组,n=7)。Sham组只经历气管插管及动静脉置管,不经历放血、复苏等过程。TCA组匀速释放总血容量的40%,然后经电刺激法室颤5 min,心肺复苏5 min后常规液体复苏治疗。SFI组在TCA组基础上于复苏后5 min进行参附注射液的干预。于放血前10 min、复苏后1、3、6、24 h检测血清TNF-α、IL-6、肌酐(Cr)、尿素氮(BUN)水平。复苏后24 h经右侧耳缘静脉注射10%氯化钾液20 mL处死猪,迅速获取肾组织标本,应用原位末端标记法(TNUEL法)检测细胞凋亡情况,免疫组织化学法检测半胱氨酸天冬氨酸蛋白酶-3(Caspase-3)的蛋白表达水平。结果TCA组中有8头猪复苏成功,SFI组和Sham组中所有猪复苏成功。与Sham组比较,TCA组血清Cr水平在复苏后24 h、BUN水平在复苏后1、3、6、24 h均明显增高(均P<0.05),TNF-α、IL-6水平在复苏后3、6、24 h明显增高(均P<0.05),复苏后24 h后肾组织细胞凋亡指数及Caspase-3表达增加(均P<0.05)。与TCA组比较,SFI组BUN水平复苏后3、6 h明显降低(均P<0.05),TNF-α、IL-6水平在复苏后3、6、24 h明显降低(均P<0.05),肾组织细胞凋亡指数和Caspase-3蛋白表达有所降低,但差异无统计学意义(均P>0.05)。结论在猪TCA复苏模型中,早期应用参附注射液能够明显减轻复苏后肾损伤。其机制可能与抑制系统炎症反应、减轻细胞凋亡有关。     

"先安未受邪之地"思想在顽痹治疗中的运用

"先安未受邪之地"思想在顽痹临床论治同样具有深远意义.顾护常人之脾胃,并于患者肝肾、脾胃脏腑亏损相关症状出现早期,予辛温苦燥之品祛风、散寒、除湿调补脾胃,益肝肾有早晚之别,早期重"补阳",稳定期及后期则以"滋阴"为主.治疗中利湿活血防痰瘀互结,减缓关节损伤,提升患者生活质量.     

复方中药制剂康赛德对海洛因依赖恒河猴脏器病变的疗效观察

目的··:探讨海洛因依赖恒河猴经用复方中药康赛德治疗后垂体、肾上腺、睾丸等脏器组织结构的恢复情况。方法··:利用光镜对海洛因依赖恒河猴在用康赛德治疗3个月后各脏器的病理学改变进行观察。结果·· :肝细胞变性在自然戒断组为3例 (3/3) ,而康赛德治疗组仅1例 (1/3)。肾上腺的病理改变在自然戒断组和治疗组均为2例 (2/3) ,不过前者病变程度较重 ,大部分皮质束状带细胞水肿 ;而后者仅为个别皮质束状带细胞水肿。睾丸病变在自然戒断组和治疗组也均为2例 (2/3) ,前者曲精细管全部萎缩 ,细胞层次减少 ,无精子形成 ,也未见间质细胞 ,间质内纤维组织增生 ;后者病变程度较轻 ,曲精细管仅是部分萎缩 ,部分管腔内有少数精子 ,可见间质细胞 ,间质内纤维组织轻度增生。附睾及垂体的病理改变在治疗组也较轻。结论··:康赛德治疗 ,可使肾上腺、睾丸、垂体等组织结构和功能尽快地得到恢复